INTRODUCTION
============

The repeated sprint ability (RSA) consists of performing subsequent sprints with a short recovery time, and is typical for athletes engaged in team sports ([@b7-jer-13-1-55]). This type of performance involves both the anaerobic and aerobic energy systems, which is the typical metabolism of most team sports, for instance during soccer competitions ([@b36-jer-13-1-55]). Several factors are alleged to foster RSA performance, they include the energy supply capacities, such as phosphocreatine resynthesis, anaerobic glycolysis and aerobic metabolism, but also hydrogen ion (H+) buffering and muscle activation ([@b19-jer-13-1-55]). Furthermore, different exercise modalities can influence the magnitude of the RSA deterioration, indeed cycle ergometry produced lower performance (20%--25% decrease), compared to the 10%--15% reduction during running exercise ([@b17-jer-13-1-55]).

Different training strategies can increase RSA ([@b7-jer-13-1-55]), but also optimal nutrition, including dietary supplementation, may improve this performance. Caffeine (Caf), for instance, enhances endurance performance ([@b15-jer-13-1-55]) but also sprint ability (SA) on cycle-ergometry ([@b35-jer-13-1-55]) and running ([@b20-jer-13-1-55]). Moreover, positive effects were detected on intermittent sprint testing, that is an exercise modality similar to the RSA, both on performance ([@b38-jer-13-1-55]), and rating of perceived exertion (RPE) ([@b11-jer-13-1-55]). Accordingly, the ergogenic effect of Caf on RSA was highlighted by [@b35-jer-13-1-55], in male team sport athletes during intermittent sprint testing and by [@b33-jer-13-1-55] in moderately trained male athletes.

Similarly to Caf, the use of branched-chain amino acids (BCAA) is well documented: on the whole, BCAA represent an energy source during intense exercise ([@b8-jer-13-1-55]), nevertheless, while the administration of BCAA combined with resistance training (RT) was confirmed to have positive effects on protein synthesis ([@b34-jer-13-1-55]), the effects on endurance and sprint exercise remain controversial. In fact, BCAA do not seem to enhance this performance directly, but rather in ameliorating fatigue toleration ([@b23-jer-13-1-55]; [@b32-jer-13-1-55]). Evidences about the ergogenic effect of arginine (Arg) are controversial. [@b3-jer-13-1-55] showed an improved oxygen consumption during progressive intensity exercise, demonstrating that Arg supplementation can be useful to increase aerobic capacity in untrained or moderately trained subjects. On the other hand, several investigations performed on healthy nonathlete subjects, did not report any benefits in cycle-ergometry performance ([@b29-jer-13-1-55]), oxygen consumption during a treadmill test ([@b5-jer-13-1-55]; [@b39-jer-13-1-55]) and metabolic ([@b29-jer-13-1-55]), hormonal or cardio-respiratory responses ([@b18-jer-13-1-55]). In addition, results from clinical trials in highly trained athletes of judo ([@b29-jer-13-1-55]; [@b40-jer-13-1-55]), tennis ([@b5-jer-13-1-55]), and cycling ([@b18-jer-13-1-55]) did not show any consistent improvement.

Overall, literature describes contrasting effects with regard to the use of Caf, BCAA, and Arg alone on exercise performance. For this reason, we aimed to compare these different components alone, combined, and versus a placebo beverage. The hypothesis is that the formulation including Caf, BCAA, and Arg leads to higher RSA performance than a single component or the placebo. To the best of our knowledge, this is the first study to examine the combined effect of a dietary supplementation formula including Caf, BCAA, and Arg on RSA performance in moderately trained soccer players.

MATERIALS AND METHODS
=====================

We recruited a group of 12 soccer players. Participants performed five trials in separate days that consisted of a battery of 11 subsequent sprints. Before each trial, subjects were administered 500 mL of dietary supplementation that consisted of the five treatment conditions (dietary supplements). Trials were performed in an indoor athletic field in order to standardize external conditions such as temperature, wind, humidity and ground characteristics, besides, all tests were carried out within one month and at the same time of the day.

Participants
------------

Twelve young men were recruited through public announcement affixed to the Sport and Exercise Medicine Division of the Department of Medicine, University of Padova (Padova, Italy). The research protocol was performed in the same Institution. Information on the purpose and procedures of the study were given to each subject, and written consent was obtained before participation. The study complied with the current laws of Italy for research on human participants and was examined and approved by the local review board.

Inclusion criteria for the participation to the study were: age between 20--30 years, being soccer players and with a training regimen of at least 4 hr per week. Exclusion criteria included any history of central nervous dysfunction, or any transitorily conditions that limited sprinting performance or the range of motion. Additionally, subjects with clinical histories of severe cardiovascular disease that could limit or contraindicate exercise, angina or related symptoms, postural hypotension (defined as a fall in arterial blood pressure when changing position \>20 mmHg in systole or \>10 mmHg in diastole) were excluded. Furthermore, subjects were asked to abstain from consuming any nutritional or dietary supplements for the whole duration of the study. Additionally, the 48 hr before any trial, participants were instructed to avoid intense or unaccustomed training sessions.

Dietary supplementation
-----------------------

The five treatment conditions were placebo (P), P + Caf (C), P + Arg (A), P + BCAA (B), P + Caf + Arg + BCAA (ALL). P consisted of a mixture of carbohydrate (26.7 g), vitamins, mineral salts, and flavorings, and served as the base for each treatment condition. C was composed of P plus 300 mg of Caf, that is an average of 4 mg/kg, which is considered an optimal threshold for caffeine efficacy ([@b21-jer-13-1-55]). A was comprised of P plus 3 g of Arg, while B was P plus 5 g of BCAA. Finally, ALL represented the combination of P with the addition of 300 mg of Caf, 3 g of Arg and 5 g of BCAA. The volume of the five beverages was 500 mL and the osmolarity was kept constant for each condition to mask the presence of different substances.

Performance measures
--------------------

Photocell gates (Alge-Timing, Lustenau, Austria) were placed in correspondence of the initial and final lines of the track, and subjects were required to start the sprint 1.5 m behind the starting line. Heart rate (HR) was registered with a Polar s810i wearable device (Polar Electro, Kempele, Finland), Oxygen saturation (OS) was measured by pulse oximetry (OxiMax NPB-40, Nellcor, Canada), finally, a capillary lactate analyzer (Lactate plus, Nova Biomedical, Waltham, MA, USA) was adopted to measure the hematic concentration of lactate (HL).

Experimental procedure
----------------------

Subjects performed 5 testing sessions in 5 different days, held approximately 1 week apart. One hr before each session, subjects consumed, with a random assignment, one of the dietary supplementations prepared in a black opaque water bottle. Both participants and assessors were blinded. Ten minutes before each testing sessions, subjects underwent a standardized warm-up consisting of 5 min of jogging, five sprints at moderate intensity and 2 min of jogging. The RSA protocol consisted of 11 maximal sprints interspersed with brief recoveries of 20 sec along a 20-m track ([@b30-jer-13-1-55]). During the recovery period, participants were instructed to return to the starting line within 20 sec.

Standardized verbal encouragement was provided throughout the sprint to minimize possible bias effects due to lack of motivation and to promote a maximal effort ([@b31-jer-13-1-55]). Physiological measures, HR, OS, and HL, were measured at baseline and after exercise, within a few seconds from the end of the last sprint, while, RPE was collected only immediately after the eleventh sprint of each trial.

Following physical performance parameters were determined: average sprint time (AST), total time (TT), peak power (PP), and average power (AP). PP and AP were calculated with the formula *P*=(0.5 M L\^2)•T-3 \[W\], whereas M is body mass, L is distance of run and T is time. Both PP and AP were also expressed for body mass (W/kg) and respectively named peak power expressed for body mass (BMPP) and average power expressed for body mass (BMAP).

Statistical analysis
--------------------

Statistical analysis was carried out using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA). Results are expressed as means± standard deviation (SD) or percentage (%). The Shapiro--Wilk test was carried out to check if data were normally distributed, in addition, Mauchly test was used to test whether the variances of the differences between conditions were equal. All dependent variables were analyzed through analysis of variance (ANOVA) for repeated measures. Following *post hoc* tests were performed with Bonferroni correction. For RPE, a Friedman 2-way ANOVA was computed, due to a nonnormal data distribution. Significance limits were set at alpha level of *P*=0.05 (80% power).

RESULTS
=======

Three out of the 12 participants dropped out from the study due to sport injuries unrelated with the experimental protocol, thus final analysis was performed exclusively on the results of the nine subjects who completed the investigation. The study population was comprised of nine male athletes, aged between 21 and 27 years-old (mean±SD, 22.6±2.1 years); an average volume of training of 7.9±3.9 hr per week was found. Mean height and weight were 182.3±8.4 cm, and 74.5±5.4 kg, respectively (body mass index, 22.5±1.7 kg/m^2^). Baseline evaluation of the physiological parameters revealed a mean HR of 68±11.6 bpm, mean OS of 99.4%±0.8%, and mean HL of 1.11±0.4 mmol/L.

Mauchly test failed on AST and TT outcomes, hence Greinhouse-Geisser correction was used to correct for violations of sphericity. The analysis showed no differences among the types of beverage in both AST (*F*=3.033; *P*=0.071) and TT (*F*=2.670; *P*= 0.86) ([Figs. 1](#f1-jer-13-1-55){ref-type="fig"}, [2](#f2-jer-13-1-55){ref-type="fig"}). Similarly within subject analysis did not detect any statistical difference in the BMAP, as well as for postexercise OS, HL, and RPE ([Table 1](#t1-jer-13-1-55){ref-type="table"}).

On the other hand, PP (*F*=3.508; *P*=0.017) and AP (*F*=2.670; *P*=0.04) as well as postexercise HR (*F*=3.011; *P*=0.032) and BMPP (*F*=3.307; *P*=0.022) showed statistical significant difference when performances were carried out under different conditions. Nevertheless, although ANOVA-Repeated Measures showed a statistical significance, the magnitude of the difference, in these variable, was not so large to determine a statistically difference in any of the pairwise comparisons. Results are reported in [Table 2](#t2-jer-13-1-55){ref-type="table"}.

DISCUSSION
==========

The aim of this study was to evaluate the acute effects of ingesting Caf, Arg, and BCAA on RSA performance, both in single or combined conditions, to assess a potential synergistic effect of these substances. The results of this experiment suggest that adding Caf, Arg, and BCAA to a CHO beverage does not improve RSA in soccer players, indeed, the consumption of these substances did not significantly improve physical performance, neither in single modality, nor when administered together, compared to the placebo condition.

A reasonable explanation for the lack of effects retrieved may rely on the adoption of a CHO drink as the base for each treatment condition, including placebo: CHO is an essential nutrient for sprint performance ([@b1-jer-13-1-55]) and its consumption, along with the other substances, may have masked the extent of decrease in performance that could have occurred with a noncaloric placebo. Anyhow, the use of a common CHO base was opted in order to evaluate the possible ergogenic effects of supplements beyond the well-established contribution from CHO consumption. Furthermore, the selection of the exercise protocol might play a key role in detecting the deterioration of RSA. In this study, the "*Coverciano*" test was chosen because of the affinity with competition-like conditions in team sports ([@b30-jer-13-1-55]), however, its short duration may have reduced the expected decline in performance, and we can speculate that adding subsequent sprint sets could extend this gap, allowing the potential effects of these substances to counteract fatigue towards the last stages of exercise.

Among the supplements we investigated, Caf can be potentially considered as the most influent in term of improving of the SA ([@b33-jer-13-1-55]; [@b35-jer-13-1-55]). Possible mechanisms for enhanced performance after Caf ingestion can include the stimulation of the sympathetic nervous system ([@b21-jer-13-1-55]), the increased heart rate, higher blood perfusion to skeletal muscles and hepatic gluconeogenesis ([@b25-jer-13-1-55]). A few studies investigating the catecholaminergic response to high intensity exercises advanced the hypothesis that caffeine might foster physical performance by increased adrenaline secretion, that would augment the glycolitic activity ([@b16-jer-13-1-55]; [@b38-jer-13-1-55]). Notwithstanding, in the same studies the higher adrenaline bio-availability did not always reflect better performance, as in our experiment, the administration of caffeine alone did not produce significant results whereas the more conservative Bonferroni *post hoc* analysis method was utilized.

The contribution of BCAA to exercise performance is ascribed to the capability of serving as an energy source: their oxidation produces alanine that is a central precursor of hepatic gluconeogenesis. Precisely, they represent the first source of aminoacids during intense exercise ([@b8-jer-13-1-55]). In the current study, BCAA ingestion did not result in better performance, in fact, the RSA protocol might have been relatively short in duration for this mechanism to occur to a sufficient extent. Despite the controversy around the ergogenic effect of Arg, as described in the introduction, previous research outlined that Arg supplementation can enhance the onset of oxygen consumption ([@b27-jer-13-1-55]), that could enclose the oxygenation deficit occurring with physical exercise and therefore reducing lactate accumulation ([@b26-jer-13-1-55]).

Results from our study evidenced that postexercise HL differed between C and ALL conditions, anyhow, these changes were not statistically significant. In literature, the ingestion of caffeine was related with an augmented HL at the end of endurance exercise ([@b2-jer-13-1-55]; [@b10-jer-13-1-55]; [@b22-jer-13-1-55]), nevertheless, studies investigating high intensity exercises report equivocal results; some of them underlined increased HL ([@b4-jer-13-1-55]; [@b12-jer-13-1-55]; [@b16-jer-13-1-55]; [@b35-jer-13-1-55]), while others did not acquaint any variations ([@b14-jer-13-1-55]; [@b16-jer-13-1-55]; [@b24-jer-13-1-55]). Interestingly, the majority of the studies reporting increased HL also detected improved performance, independently from training status of participants, as it is confirmed by our results.

It has recently been suggested that the accumulation of lactate and other metabolic byproducts could be diminished by the production of nitric oxide ([@b9-jer-13-1-55]). Arg might play a role in this mechanism, even if there is still lack of evidence about its capability of modifying blood flow in healthy human beings. A few studies found postexercise metabolites unaltered after Arg consumption, compared to placebo ([@b29-jer-13-1-55]; [@b40-jer-13-1-55]), which is in accord to the weak response of HL measured after Arg administration in the current experiment.

The remaining postexercise physiological parameters, HR and OS, did not show any relevant trendline between treatments. RPEs associated with BCAA showed a mild reduction tendency, despite nonsignificant, in agreement with previous research on fatigue toleration ([@b23-jer-13-1-55]; [@b32-jer-13-1-55]; [@b37-jer-13-1-55]).

In conclusion, it should be acknowledged that an inversion of tendency in mean sprint times was ascertained for each treatment condition in the last sprints. This phenomena could be explained on the basis of a psychological and motivational incentive arising from the termination of the trial; some authors suggested that performance is influenced by athletes' consciousness of the duration of the protocol ([@b6-jer-13-1-55]).

Study limitations
-----------------

The sample size represents a structural limit of this study. The low number of participants is a resultant of the experimental design selection; an acute intervention design was preferred to limit the confounding variables such as physical fitness of participants, type of nutrition throughout the study and environmental factors. Moreover, the study design resulted in optimal compliance of subjects and served as a precompetition simulation, that was the objective of the research topic. Lastly, it must be acknowledged that other nutritional supplements could have been examined for the study, foremost creatine, whose ergogenic potential in physical performance is widely investigated, though, its acute effects on performance are controversial ([@b13-jer-13-1-55]). Besides, creatine-caffeine coingestion was described to counteract the ergogenic effect of caffeine ([@b28-jer-13-1-55]).

In summary, the nutritional supplement designed for this study, composed of Caf, Arg, and BCAA, did not enhance RSA performance compared to the placebo condition. Despite a slight improvement trend line was retrieved after the ingestion of the experimental supplement, data analysis revealed no statistical differences in any performance parameters taken for the audit. Null effects were found on RSA whether the substances were administered in single modality or all together: a synergistic effect does not seem to exist for these substances. Although nutritional supplements containing carbohydrate, Caf, Arg, and BCAA are currently available on the market and amply advertised for team sports, the results of this study do not support the hypothesis that adding Caf, Arg, and BCAA to a carbohydrate drink is more beneficial to RSA than ingesting carbohydrate alone in recreationally trained young men. Future perspectives for consolidating the retrieved evidences concern the enlargement of sample size and the extension of exercise duration. The slight decrement of performance throughout the entire protocol suggest that prolonging the duration of exercise by adding sprint sets to the original protocol would increase the efficacy in testing the effects of nutritional aids on RSA.
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![Primary physical performance outcomes: average sprint time. CHO, carbohydrates only (placebo); C, carbohydrates plus caffeine; A, carbohydrates plus arginine; B, carbohydrates plus branched chain amino acids; All, carbohydrate plus caffeine, arginine and branched chain amino acids.](jer-13-1-55f1){#f1-jer-13-1-55}

![Primary physical performance outcomes: total time. CHO, carbohydrates only (placebo); C, carbohydrates plus caffeine; A, carbohydrates plus arginine; B, carbohydrates plus branched chain amino acids; All, carbohydrate plus caffeine, arginine, and branched chain amino acids.](jer-13-1-55f2){#f2-jer-13-1-55}

###### 

Physiological and performance outcomes

        Body mass average power (W/kg)   Postexercise hematic lactate (mmol/L)   Postexercise oxygen saturation (%)   Rating of perceived effort (RPE)   Peak power (W)   Average power (W)   Postexercise heart rate (bpm)   Body mass peak power (W/kg)
  ----- -------------------------------- --------------------------------------- ------------------------------------ ---------------------------------- ---------------- ------------------- ------------------------------- -----------------------------
  P     7.12±1.78                        6.20±3.18                               96.22±1.30                           13.66±1.65                         596.11±133.82    530.60±138.47       167.22±9.97                     8.01±1.76
  C     7.55±1.66                        7.18±3.26                               96.55±2.12                           13.55±1.13                         638.33±147.12    564.17±135.87       156.44±14.12                    8.56±1.94
  A     7.26±1.57                        6.45±2.40                               97.22±0.66                           13.55±0.72                         623.23±129.96    542.45±128.46       162.88±14.72                    8.37±1.72
  B     7.26±1.37                        5.92±2.01                               96.44±1.13                           13.33±1.41                         604.13±102.68    540.23±95.72        163.11±13.86                    8.12±1.48
  All   7.66±1.35                        8.05±2.41                               96.55±1.66                           13.66±1.22                         655.97±126.15    572.91±115.23       165.22±16.17                    8.78±1.54

Values are presented as mean±standard deviation.

P, carbohydrate only; C, carbohydrates plus caffeine; A, carbohydrates plus arginine; B, carbohydrates plus branched chain amino acids; All, carbohydrate plus caffeine, arginine, and branched chain amino acids.

Within group analyses did not found any statistically significant change after the consumption of each nutritional supplement.

###### 

Physiological and performance outcomes according to the within subject analysis (PP, AP, HR, BMPP)

        Peak power (W)   Average power (W)   Postexercise heart rate (bpm)   Body mass peak power (W/kg)
  ----- ---------------- ------------------- ------------------------------- -----------------------------
  P     596.11±133.82    530.60±138.47       167.22±9.97                     8.01±1.76
  C     638.33±147.12    564.17±135.87       156.44±14.12                    8.56±1.94
  A     623.23±129.96    542.45±128.46       162.88±14.72                    8.37±1.72
  B     604.13±102.68    540.23±95.72        163.11±13.86                    8.12±1.48
  All   655.97±126.15    572.91±115.23       165.22±16.17                    8.78±1.54

Values are presented as mean±standard deviation.

This table highlights the physiological and performance outcomes that resulted in significant difference, after the consumption of supplements, according to the Within Subject Analysis (PP, AP, HR, BMPP).

P, carbohydrate only; C, carbohydrates plus caffeine; A, carbohydrates plus arginine; B, carbohydrates plus branched chain amino acids; All, carbohydrate plus caffeine, arginine and branched chain amino acids; PP, peak power; AP, average sprint time; HR, heart rate, BMPP, body mass peak power.
